乳腺癌易感基因1表达与吉非替尼治疗表皮生长因子受体基因突变型晚期非小细胞肺癌疗效的关系  

The relationship between the expression of BRCA1 gene and the efficacy of Gefitinib in treatment of advanced non-small cell lung cancer with epithelial growth factor receptor mutation

作　　者：张顺达[1] 冯卫能[1] 冼海兵[1] 伍婧[1] 唐溢聪[1] 陈泽程[1] 邓燕明[1] 

机构地区：[1]佛山市第一人民医院(中山大学附属佛山医院),佛山528000

出　　处：《内科急危重症杂志》2015年第5期330-332,338,共4页Journal of Critical Care In Internal Medicine

基　　金：广东省科技厅科技计划项目(No:20120318077);吴阶平医学基金项目(No:320.6799.1115);佛山市卫生局医学科研项目(No:2014051)

摘　　要：目的:探讨乳腺癌易感基因1(BRCA1)表达与吉非替尼治疗表达生长因子受体(EGFR)突变型晚期非小细胞肺癌患者的疗效关系。方法:纳入EGFR突变型晚期非小细胞肺癌患者50例,口服吉非替尼进行治疗,直至疾病进展或者出现不可耐受的毒副反应,采用免疫组织化学方法、RT-PCR检测EGFR突变型晚期非小细胞肺癌患者中BRCA1的表达情况并收集50例患者的预后情况。结果:不同预后的EGFR突变型晚期非小细胞肺癌患者中,BRCA1阳性细胞表达及BRCA1mRNA表达水平随着预后的不良而增加;BRCA1高表达率为36.00%,BRCA1高表达组吉非替尼有效率低于BRCA1低表达组(33.33%vs 68.75%,P<0.05)。结论:吉非替尼治疗EGFR突变型晚期非小细胞肺癌患者中,BRCA1低表达患者受益比高表达患者明显,BRCA1可以作为吉非替尼治疗EGFR突变型晚期非小细胞肺癌疗效的预测因素。Objective： To investigate the relationship between the expression of the breast cancer 1（ BRCA1） and the efficacy of Gefitinib in treatment of advanced non-small cell lung cancer（ NSCLC） patients with epithelial growth factor receptor（ EGFR） mutation. Methods： Fifty advanced NSCLC patients with EGFR mutation were received oral Gefitinib treatment until progression of the disease or intolerable drug toxicity occured. The expressions of BRCA1 in these patients were detected by immunohistochemistry method,TR-PCR detected EGFR mutation. The therapeutic effect of Gefitinib for advanced NSCLC patients with EGFR mutation was analyzed by collecting the clinical data retrospectively. Results： BRCA1 expression rate was 36. 00%（ 18 /50）. The response rate was 33. 33%（ 6 /18） in high BRCA1 expression group and was 68. 75%（ 22 /32） in low BRCA1 expression group,and the difference was statistically significant（ P〈0. 05）. Conclusions： In treatment of Gefitinib for advanced NSCLC patients with EGFR mutation,patients with low BRCA1 expression were more significantly benefit than those with high BRCA1 expression. BRCA1 may be a predictive factor for efficacy of Gefitinib treatment for advanced NSCLC patients with EGFR mutation.

关 键 词：BRCA1 EGFR 突变型晚期非小细胞肺癌 吉非替尼 

分 类 号：R58[医药卫生—内分泌]